AstraZeneca (LON:AZN) received a GBX 7,100 ($92.77) price objective from equities research analysts at JPMorgan Chase & Co. in a research report issued on Friday, March 29th, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 22.10% from the company’s previous close.
A number of other research firms have also weighed in on AZN. Deutsche Bank reaffirmed a “buy” rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a research report on Monday, February 18th. Bryan, Garnier & Co downgraded shares of AstraZeneca to a “neutral” rating in a research note on Friday, February 22nd. Shore Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday, December 7th. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Thursday, February 14th. Finally, Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a research note on Monday, March 18th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of GBX 6,362.70 ($83.14).
Shares of AstraZeneca stock traded down GBX 99 ($1.29) during trading hours on Friday, reaching GBX 5,815 ($75.98). 2,258,433 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 1 year low of GBX 4,928.50 ($64.40) and a 1 year high of GBX 6,540 ($85.46). The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31. The firm has a market capitalization of $76.28 billion and a P/E ratio of 34.21.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: What is intrinsic value?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.